Use of interferon-alpha-induced dendritic cells in the therapy of patients with malignant brain gliomas

Bull Exp Biol Med. 2007 Apr;143(4):528-34. doi: 10.1007/s10517-007-0172-1.


Clinical and immunological analysis of the efficiency of combined immunotherapy with the use dendritic cells for the treatment of malignant glioma of the brain was carried out. Dendritic cells generated in the presence of granulocyte-macrophage CSF and IFN-alpha retain their functional characteristics in patients with gliomas, which suggests the possibility of their use for the treatment of malignant tumors (glioma) of the brain. Combined therapy using interferon-induced dendritic cells was associated with generation of antigen-specific immune response during vaccinations. The results indicate satisfactory tolerance of combined immunotherapy using dendritic cells and the absence of toxic side effects at the stage of adoptive immunotherapy and at the stage of vaccinations with dendritic cells. Clinical trials showed that vaccinations with dendritic cells included into combined immunotherapy improved the quality of life and survival of patients with malignant gliomas.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Brain Neoplasms / immunology
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy*
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology*
  • Female
  • Flow Cytometry
  • Glioma / immunology
  • Glioma / pathology
  • Glioma / therapy*
  • Humans
  • Immunophenotyping
  • Immunotherapy / methods*
  • Immunotherapy, Adoptive / methods
  • Interferon-alpha / immunology
  • Interferon-alpha / pharmacology*
  • Male
  • Middle Aged
  • Pilot Projects
  • Quality of Life
  • Survival Analysis
  • Treatment Outcome


  • Interferon-alpha